Icaritin suppresses multiple myeloma, by inhibiting IL-6/JAK2/STAT3

Shicong Zhu; Zhihua Wang; Zijian Li; Hongling Peng; Yunya Luo; Mingyang Deng; Ruijuan Li; Chongwen Dai; Yunxiao Xu; Sufang Liu; Guangsen Zhang

doi:10.18632/oncotarget.3399

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Icaritin suppresses multiple myeloma, by inhibiting IL-6/JAK2/STAT3

Shicong Zhu, Zhihua Wang, Zijian Li, Hongling Peng, Yunya Luo, Mingyang Deng, Ruijuan Li, Chongwen Dai, Yunxiao Xu, Sufang Liu and Guangsen Zhang _

PDF | HTML | How to cite

Oncotarget. 2015; 6:10460-10472. https://doi.org/10.18632/oncotarget.3399

Metrics: PDF 4706 views | HTML 5142 views | ?

Abstract

Shicong Zhu1,*, Zhihua Wang1,*, Zijian Li1,2, Hongling Peng1, Yunya Luo1, Mingyang Deng1, Ruijuan Li1, Chongwen Dai1, Yunxiao Xu1, Sufang Liu1, Guangsen Zhang1

1Division of Hematology, Institute of Molecular Hematology, The Second Xiang-ya Hospital, Central South University, Changsha, Hunan, China

2Division of Hematology, The First Affiliated Hospital, Lanzhou University, Lanzhou, Gansu, China

*These authors have contributed equally to this work

Corresponding to:

Guangsen Zhang, e-mail: [email protected]

Keywords: icaritin, multiple myeloma, antitumor activities, IL6/JAK2/STAT3 signaling

Received: January 19, 2015 Accepted: February 15, 2015 Published: March 16, 2015

ABSTRACT

Icaritin is an active prenylflavonoid derived from Epimedium genus, a traditional Chinese medicine. Icaritin has a wide range of pharmacological and biological activities, including cardiovascular function improvement, hormone regulation and antitumor activity. Here, we investigated the effect of icaritin on multiple myeloma (MM) in vitro and in vivo. Icaritin inhibited cell growth of MM cell line and primary MM cells. In contrast, icaritin had low or no cytotoxic effect on normal hematopoiesis. We also demonstrated that in MM xenograft mouse models, icaritin suppressed tumor growth and decreased serum IL-6 and IgE levels, but did not show adverse reactions such as body weight loss. The anti-MM activity of icaritin was mainly mediated by inhibiting IL-6/JAK2/STAT3 signaling. We suggest that icaritin can be further tested in clinical trials in MM.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3399

Publication Alerts

Research Papers:

Icaritin suppresses multiple myeloma, by inhibiting IL-6/JAK2/STAT3

Abstract